Celyad Oncology SA
XBRU:CYAD

Watchlist Manager
Celyad Oncology SA Logo
Celyad Oncology SA
XBRU:CYAD
Watchlist
Price: 0.6 EUR -16.43% Market Closed
Market Cap: 24.9m EUR
Have any thoughts about
Celyad Oncology SA?
Write Note

Intrinsic Value

CYAD's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one CYAD stock under the Base Case scenario is 0.02 EUR. Compared to the current market price of 0.6 EUR, Celyad Oncology SA is Overvalued by 97%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

CYAD Intrinsic Value
0.02 EUR
Overvaluation 97%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Celyad Oncology SA

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for CYAD cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about CYAD?
Bearish
Neutral
Bullish
Discover Undervalued Stocks
Biotechnology Industry

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Celyad Oncology SA

Provide an overview of the primary business activities
of Celyad Oncology SA.

What unique competitive advantages
does Celyad Oncology SA hold over its rivals?

What risks and challenges
does Celyad Oncology SA face in the near future?

Summarize the latest earnings call
of Celyad Oncology SA.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Celyad Oncology SA.

Provide P/S
for Celyad Oncology SA.

Provide P/E
for Celyad Oncology SA.

Provide P/OCF
for Celyad Oncology SA.

Provide P/FCFE
for Celyad Oncology SA.

Provide P/B
for Celyad Oncology SA.

Provide EV/S
for Celyad Oncology SA.

Provide EV/GP
for Celyad Oncology SA.

Provide EV/EBITDA
for Celyad Oncology SA.

Provide EV/EBIT
for Celyad Oncology SA.

Provide EV/OCF
for Celyad Oncology SA.

Provide EV/FCFF
for Celyad Oncology SA.

Provide EV/IC
for Celyad Oncology SA.

Show me price targets
for Celyad Oncology SA made by professional analysts.

What are the Revenue projections
for Celyad Oncology SA?

How accurate were the past Revenue estimates
for Celyad Oncology SA?

What are the Net Income projections
for Celyad Oncology SA?

How accurate were the past Net Income estimates
for Celyad Oncology SA?

What are the EPS projections
for Celyad Oncology SA?

How accurate were the past EPS estimates
for Celyad Oncology SA?

What are the EBIT projections
for Celyad Oncology SA?

How accurate were the past EBIT estimates
for Celyad Oncology SA?

Compare the revenue forecasts
for Celyad Oncology SA with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Celyad Oncology SA and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Celyad Oncology SA against its competitors.

Analyze the profit margins
(gross, operating, and net) of Celyad Oncology SA compared to its peers.

Compare the P/E ratios
of Celyad Oncology SA against its peers.

Discuss the investment returns and shareholder value creation
comparing Celyad Oncology SA with its peers.

Analyze the financial leverage
of Celyad Oncology SA compared to its main competitors.

Show all profitability ratios
for Celyad Oncology SA.

Provide ROE
for Celyad Oncology SA.

Provide ROA
for Celyad Oncology SA.

Provide ROIC
for Celyad Oncology SA.

Provide ROCE
for Celyad Oncology SA.

Provide Gross Margin
for Celyad Oncology SA.

Provide Operating Margin
for Celyad Oncology SA.

Provide Net Margin
for Celyad Oncology SA.

Provide FCF Margin
for Celyad Oncology SA.

Show all solvency ratios
for Celyad Oncology SA.

Provide D/E Ratio
for Celyad Oncology SA.

Provide D/A Ratio
for Celyad Oncology SA.

Provide Interest Coverage Ratio
for Celyad Oncology SA.

Provide Altman Z-Score Ratio
for Celyad Oncology SA.

Provide Quick Ratio
for Celyad Oncology SA.

Provide Current Ratio
for Celyad Oncology SA.

Provide Cash Ratio
for Celyad Oncology SA.

What is the historical Revenue growth
over the last 5 years for Celyad Oncology SA?

What is the historical Net Income growth
over the last 5 years for Celyad Oncology SA?

What is the current Free Cash Flow
of Celyad Oncology SA?

Discuss the annual earnings per share (EPS)
trend over the past five years for Celyad Oncology SA.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Celyad Oncology SA

Current Assets 11.1m
Cash & Short-Term Investments 7m
Receivables 2.8m
Other Current Assets 1.3m
Non-Current Assets 5.2m
PP&E 1.8m
Intangibles 390k
Other Non-Current Assets 2.9m
Current Liabilities 2.9m
Accounts Payable 1.2m
Accrued Liabilities 496k
Other Current Liabilities 1.2m
Non-Current Liabilities 7m
Long-Term Debt 902k
Other Non-Current Liabilities 6.1m
Efficiency

Earnings Waterfall
Celyad Oncology SA

Revenue
72k EUR
Cost of Revenue
-34k EUR
Gross Profit
38k EUR
Operating Expenses
-7.8m EUR
Operating Income
-7.8m EUR
Other Expenses
43k EUR
Net Income
-7.8m EUR

Free Cash Flow Analysis
Celyad Oncology SA

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

CYAD Profitability Score
Profitability Due Diligence

Celyad Oncology SA's profitability score is 17/100. The higher the profitability score, the more profitable the company is.

17/100
Profitability
Score

Celyad Oncology SA's profitability score is 17/100. The higher the profitability score, the more profitable the company is.

CYAD Solvency Score
Solvency Due Diligence

Celyad Oncology SA's solvency score is 60/100. The higher the solvency score, the more solvent the company is.

Negative Net Debt
Short-Term Solvency
Low D/E
Long-Term Solvency
60/100
Solvency
Score

Celyad Oncology SA's solvency score is 60/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CYAD Price Targets Summary
Celyad Oncology SA

There are no price targets for CYAD.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for CYAD?

Click here to dive deeper.

Dividends

Celyad Oncology SA
does not pay dividends
Shareholder Yield

Current shareholder yield for CYAD is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Celyad Oncology SA Logo
Celyad Oncology SA

Country

Belgium

Industry

Biotechnology

Market Cap

24.9m EUR

Dividend Yield

0%

Description

Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The company is headquartered in Mont-Saint-Guibert, Brabant-Wallon and currently employs 88 full-time employees. The company went IPO on 2013-07-05. The firm is a clinical-stage biotechnology company focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The firm develops allogeneic and autologous CAR T cell therapy candidates for cancer patients with hematological malignancies and solid tumors. The firm's product, CYAD-101 is a NKG2D receptor-based CAR T, which incorporates non-gene edited allogeneic TIM technology, for the treatment of refractory metastatic colorectal cancer (mCRC). The company also develops short hairpin RNA (shRNA)-based allogeneic CAR T candidate CYAD-211 for the treatment of relapsed or refractory multiple myeloma (r/r MM). Its autologous CAR T franchise is evaluating NKG2D receptor CAR T candidate CYAD-02 for the treatment of relapsed or refractory acute myeloid leukemia (r/r AML) and myelodysplastic syndromes (MDS).

Contact

BRABANT-WALLON
Mont-Saint-Guibert
Axis Business Park Rue Edouard Belin 2
+3210394100.0
www.celyad.com

IPO

2013-07-05

Employees

88

Officers

Co-Founder & Executive Director
Mr. Michel E. J. Lussier BME, M.B.A., M.S., MS BME
Chief Executive Officer
Mr. Matthew R. Kane
Vice President of Finance & Administration
Mr. David Georges
Communications & Investor Relations Director
Sara Zelkovic
Head of Legal
Ms. An Phan
Head of Intellectual Property
Mr. Hannes Iserentant
Show More
Head of R&D
Mr. Eytan Breman
Corporate Secretary
Mr. Philippe Dechamps
Show Less

See Also

Discover More
What is the Intrinsic Value of one CYAD stock?

The intrinsic value of one CYAD stock under the Base Case scenario is 0.02 EUR.

Is CYAD stock undervalued or overvalued?

Compared to the current market price of 0.6 EUR, Celyad Oncology SA is Overvalued by 97%.

Back to Top